Telavancin’s “Complete Response” Letter Calls For Pregnancy-Focused REMS
Executive Summary
After a three-day, three-drug advisory committee in November, the last sponsor standing - or at least the last to get a "complete response" letter from FDA - may be in the best position to move forward with its complicated skin and skin structure infections antibiotic
You may also be interested in...
FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS
A Risk Evaluation and Mitigation Strategy that addresses the teratogenicity of Theravance’s Vibativ enabled FDA to manage an internal disagreement that pitted the drug’s risk to the unborn against the public health need for new antibiotics.
FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS
A Risk Evaluation and Mitigation Strategy that addresses the teratogenicity of Theravance’s Vibativ enabled FDA to manage an internal disagreement that pitted the drug’s risk to the unborn against the public health need for new antibiotics.
Astellas, Theravance Get U.S. Approval With Vibativ, But HAP Indication Could Be Pushed To 2010
Japan's Astellas and Theravance's Vibativ (telavancin) gained U.S. FDA approval Sept. 11 for complicated skin infections, but an indication that will more sharply differentiate the drug may not see action until early 2010